Switch theme
Sign up to access all valuation multiples
Square Pharmaceuticals PLC is a Bangladesh-based pharmaceutical company engaged in the manufacturing and marketing of generic pharmaceuticals products, Basic chemical products, and animal health products. The company operates in one segment, which is the business of developing, manufacturing, and marketing drugs for health care for all living species. It manufactures drugs like paracetamol, clotrimazole, antiallergic, Nitroglycerin, xylometazoline HCl, erythromycin, and various other drugs. Company also provides devices such as AnsuPen and AnsuPen Twist. The company operates in Bangladesh and sells its products locally and internationally.
1964
12.5K+
LTM Revenue $636M
LTM EBITDA $181M
$1.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Square Pharma has a last 12-month revenue (LTM) of $636M and a last 12-month EBITDA of $181M.
In the most recent fiscal year, Square Pharma achieved revenue of $581M and an EBITDA of $210M.
Square Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Square Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $636M | XXX | $581M | XXX | XXX | XXX |
| Gross Profit | $301M | XXX | $274M | XXX | XXX | XXX |
| Gross Margin | 47% | XXX | 47% | XXX | XXX | XXX |
| EBITDA | $181M | XXX | $210M | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 36% | XXX | XXX | XXX |
| EBIT | $163M | XXX | $151M | XXX | XXX | XXX |
| EBIT Margin | 26% | XXX | 26% | XXX | XXX | XXX |
| Net Profit | $197M | XXX | $173M | XXX | XXX | XXX |
| Net Margin | 31% | XXX | 30% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Square Pharma's stock price is BDT 201 (or $2).
Square Pharma has current market cap of BDT 178B (or $1.5B), and EV of BDT 130B (or $1.1B).
See Square Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.1B | $1.5B | XXX | XXX | XXX | XXX | $0.22 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Square Pharma has market cap of $1.5B and EV of $1.1B.
Square Pharma's trades at 1.8x EV/Revenue multiple, and 5.5x EV/EBITDA.
Equity research analysts estimate Square Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Square Pharma has a P/E ratio of 7.5x.
See valuation multiples for Square Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| EV (current) | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | 1.8x | XXX | XXX | XXX |
| EV/EBITDA | 5.9x | XXX | 5.5x | XXX | XXX | XXX |
| EV/EBIT | 6.6x | XXX | 6.8x | XXX | XXX | XXX |
| EV/Gross Profit | 3.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 7.5x | XXX | 7.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 9.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSquare Pharma's last 12 month revenue growth is 10%
Square Pharma's revenue per employee in the last FY averaged $47K, while opex per employee averaged $10K for the same period.
Square Pharma's rule of 40 is 47% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Square Pharma's rule of X is 53% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Square Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 32% | XXX | XXX | XXX |
| EBITDA Growth | 18% | XXX | -1% | XXX | XXX | XXX |
| Rule of 40 | 47% | XXX | 42% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 53% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $47K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $10K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 21% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Square Pharma acquired XXX companies to date.
Last acquisition by Square Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Square Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Square Pharma founded? | Square Pharma was founded in 1964. |
| Where is Square Pharma headquartered? | Square Pharma is headquartered in Bangladesh. |
| How many employees does Square Pharma have? | As of today, Square Pharma has 12.5K+ employees. |
| Is Square Pharma publicy listed? | Yes, Square Pharma is a public company listed on DHA. |
| What is the stock symbol of Square Pharma? | Square Pharma trades under SQURPHARMA ticker. |
| Who are competitors of Square Pharma? | Similar companies to Square Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Square Pharma? | Square Pharma's current market cap is $1.5B |
| What is the current revenue of Square Pharma? | Square Pharma's last 12 months revenue is $636M. |
| What is the current revenue growth of Square Pharma? | Square Pharma revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Square Pharma? | Current revenue multiple of Square Pharma is 1.7x. |
| Is Square Pharma profitable? | Yes, Square Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Square Pharma? | Square Pharma's last 12 months EBITDA is $181M. |
| What is Square Pharma's EBITDA margin? | Square Pharma's last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of Square Pharma? | Current EBITDA multiple of Square Pharma is 5.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
